IntoCell was founded with a daring vision to bring innovative ADC platform technologies to the market, leveraging original concepts and technical expertise, diverging from the conventional small molecule-based drug discovery and development. The leadership team at IntoCell possesses prior management involvement in co-establishing a venture firm that later became publicly listed on the KOSDAQ stock exchange. Through the fusion of extensive know-how in successful ADC technology development and a wide-ranging industry connections, we are confident in the realization of our vision.